Welcome to our dedicated page for Celldex Therapeutics SEC filings (Ticker: CLDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Celldex Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing antibody-based therapeutics in immunology and mast cell-mediated disease. Its 8-K reports furnish financial results and corporate updates, including clinical and regulatory disclosures for barzolvolimab programs and other pipeline candidates, as well as material-event and capital-structure disclosures related to common stock financing.
Proxy materials describe annual stockholder voting matters, director elections, auditor ratification, executive compensation and equity incentive plan proposals. The filing record also identifies Celldex common stock, par value $.001, trading under CLDX on the Nasdaq Capital Market.
Vanguard Capital Management filed a Schedule 13G disclosing beneficial ownership of 3,446,795 shares of Celldex Therapeutics Inc common stock. The filing states this equals 5.17% of the class, with sole dispositive power over 3,446,795 shares and sole voting power over 485,900 shares.
The filing attributes ownership to Vanguard Capital Management and affiliated Vanguard entities and is signed by Ashley Grim on 04/29/2026.
Celldex Therapeutics, Inc. is asking stockholders to approve several items at its virtual 2026 Annual Meeting on June 25, 2026 at 9:00 a.m. Eastern. Only holders of its 78,492,072 outstanding common shares as of April 27, 2026 may vote.
Stockholders will vote on electing nine directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, approving an amendment to the 2021 Omnibus Equity Incentive Plan that increases shares reserved for issuance by 3,400,000 to 12,900,000 and clarifies tax withholding, and an advisory say-on-pay vote for named executive officer compensation.
The proxy describes Celldex as a clinical-stage biotechnology company focused on antibody-based immunotherapies, led by barzolvolimab in multiple Phase 3 and Phase 2 programs and CDX-622 in early clinical development. It highlights a largely independent nine-member board, active committees overseeing risk, compensation and science, and policies on ethics, insider trading, stock ownership, and sustainability. Celldex ended 2025 with $519 million in cash, cash equivalents and marketable securities, which it expects to fund operations through 2027.
Celldex Therapeutics is offering 10,345,000 shares of common stock at $29.00 per share. The prospectus supplement states the public offering price of $29.00, gross proceeds of $300,005,000, and estimated net proceeds to the company of approximately $281.8 million. The underwriters have a 30-day option to purchase up to an additional 1,551,750 shares. Shares outstanding after the offering are shown as 76,894,442 (or 78,446,192 if the option is exercised), based on 66,549,442 shares outstanding as of December 31, 2025. The company intends to use proceeds to fund commercial readiness for barzolvolimab, continue clinical and preclinical development, grow its bispecific antibody platform, and for general corporate purposes.
Celldex Therapeutics entered an underwriting agreement for a public offering of 10,345,000 shares of common stock at $29.00 per share. The company expects gross proceeds of about $300 million and net proceeds of approximately $282 million, before any exercise of the underwriters’ option.
The underwriters have a 30-day option to buy up to an additional 1,551,750 shares at the same price, and the deal is expected to close on or about April 6, 2026, subject to customary conditions. Celldex plans to use the net proceeds, together with existing cash and investments, to support potential commercial launch of barzolvolimab for CSU in the United States if approved, further clinical and preclinical development of its pipeline, expansion of its bispecific antibody platform, additional pipeline programs, and general corporate purposes.
Celldex Therapeutics is offering shares of its common stock pursuant to a preliminary prospectus supplement. The supplement describes an at-the-market style shelf offering under the company’s existing registration and notes Nasdaq symbol CLDX with a last reported sale price of $31.72 per share on March 31, 2026.
The document discloses 66,549,442 shares outstanding as of December 31, 2025, outstanding options of 9,134,278 shares (weighted-average exercise price $26.49), and 2,753,587 shares reserved under equity plans. It states net tangible book value of $500.0 million or $7.51 per share as of December 31, 2025. The prospectus supplement leaves the offered share amount, offering price and estimated proceeds blank in the provided excerpt.
Celldex Therapeutics Inc ownership update: The Vanguard Group amended its Schedule 13G to report 0 shares beneficially owned of Common Stock, representing 0% of the class, following an internal realignment effective January 12, 2026. The filing notes certain Vanguard subsidiaries now report separately.
Celldex Therapeutics amendment reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen beneficially owned 1,758,357 shares of common stock, representing 2.6% as of the close of business on December 31, 2025. The filing attributes shared voting and shared dispositive power of 1,758,357 shares to the reporting persons and notes Point72 entities act as investment manager and general partner. The statement clarifies these reporting persons hold no sole voting or dispositive power and provides their principal business address.
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on mast cell biology, developing monoclonal and bispecific antibodies for severe inflammatory, allergic and autoimmune diseases. Its lead drug, barzolvolimab (CDX‑0159), targets the KIT receptor to inhibit and deplete mast cells, aiming to treat conditions where current therapies are inadequate.
Barzolvolimab has shown rapid, durable and clinically meaningful Phase 1/2 results in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), and is now in large global Phase 3 programs in CSU and Phase 3 in cold urticaria and symptomatic dermographism, plus Phase 2 trials in prurigo nodularis and atopic dermatitis. Celldex discontinued eosinophilic esophagitis after mast cell depletion did not translate into symptom benefit but is advancing CDX‑622, a bispecific targeting TSLP and SCF, through Phase 1. The company is scaling up commercial manufacturing, building its commercial organization, and relies on key licenses such as a Yale agreement for barzolvolimab, while operating in a highly competitive dermatology and immunology landscape. As of June 30, 2025, the aggregate market value of common stock held by non‑affiliates was $1.3 billion, with 66,566,346 shares outstanding as of February 13, 2026.
Celldex Therapeutics reported wider losses for the fourth quarter and full year 2025 as it accelerated investment in its immunology pipeline, led by barzolvolimab in chronic urticarias. Fourth quarter revenue was $0.1 million, while research and development expenses rose to $75.3 million and general and administrative costs to $11.9 million.
The company posted a fourth quarter net loss of $81.3 million, or ($1.22) per share, and a full-year 2025 net loss of $258.8 million, or ($3.90) per share. Cash, cash equivalents and marketable securities were $518.6 million as of December 31, 2025, and Celldex expects this to fund operations through 2027.
Operationally, Celldex completed enrollment in both Phase 3 chronic spontaneous urticaria studies six months ahead of guidance, with topline data expected in Q4 2026 and a planned BLA submission in 2027. Enrollment also finished in Phase 2 prurigo nodularis and atopic dermatitis trials, and the company advanced its bispecific antibody CDX-622 with ongoing Phase 1 studies, setting up multiple key data readouts in 2026.